Allianz Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Allianz Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,300	Closed	-$744K	–	2292
2023 Q2	$744K	Hold	7,300	–	–	﹤0.01%	1632
2023 Q1	$664K	Buy	+7,300	New	+$428K	﹤0.01%	1817
2022 Q1	–	Sell	-9,030	Closed	-$238K	–	2712
2021 Q4	$238K	Sell	9,030 -2,000	-18%	-$155K	﹤0.01%	2434
2021 Q3	$1.11M	Hold	11,030	–	–	﹤0.01%	1880
2021 Q2	$1.56M	Sell	11,030 -300	-3%	-$33.9K	﹤0.01%	1560
2021 Q1	$1.13M	Hold	11,330	–	–	﹤0.01%	1599
2020 Q4	$1.4M	Buy	11,330 +2,300	+25%	+$302K	﹤0.01%	1401
2020 Q3	$880K	Sell	9,030 -21,753	-71%	-$2.72M	﹤0.01%	1463
2020 Q2	$4.8M	Buy	30,783 +8,354	+37%	+$1.27M	0.01%	1228
2020 Q1	$3.24M	Buy	22,429 +6,178	+38%	+$1.19M	﹤0.01%	1354
2019 Q4	$3.32M	Buy	+16,251	New	+$2.96M	﹤0.01%	1668

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allianz Asset Management's RETA Position: Q3 2023 in Review

Allianz Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,300 shares — an estimated $744K sold.

Allianz Asset Management first reported a position in RETA in Q4 2019 and held it in 11 quarters. The position peaked at $4.8M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Allianz Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Allianz Asset Management sold 7,300 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $744K.
Allianz Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 11 quarters.
Allianz Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.8M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Allianz Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.